A phase II dose-ranging study of mirabegron in patients with overactive bladder.
Chapple CR, Dvorak V, Radziszewski P, Van Kerrebroeck P, Wyndaele JJ, Bosman B, Boerrigter P, Drogendijk T, Ridder A, Van Der Putten-Slob I, Yamaguchi O; Dragon Investigator Group.
Chapple CR, et al.
Int Urogynecol J. 2013 Sep;24(9):1447-58. doi: 10.1007/s00192-013-2042-x. Epub 2013 Mar 8.
Int Urogynecol J. 2013.
PMID: 23471546
Free PMC article.
Clinical Trial.